Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC), with 25–50% of patients expected to achieve a pathologic response. Validated biomarkers predictive of response are currently lacking. OBJECTIVE: To discover...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol
Main Authors: Plimack, Elizabeth R., Dunbrack, Roland L., Brennan, Timothy A., Andrake, Mark D., Zhou, Yan, Serebriiskii, Ilya G., Slifker, Michael, Alpaugh, Katherine, Dulaimi, Essel, Palma, Norma, Hoffman-Censits, Jean, Bilusic, Marijo, Wong, Yu-Ning, Kutikov, Alexander, Viterbo, Rosalia, Greenberg, Richard E., Chen, David Y.T., Lallas, Costas D., Trabulsi, Edouard J., Yelensky, Roman, McConkey, David J., Miller, Vincent A., Golemis, Erica A., Ross, Eric A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4764095/
https://ncbi.nlm.nih.gov/pubmed/26238431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.07.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados